An alternative approach for the currently used replacement therapy in dentistry is to apply materials that restore tooth tissue. Among them, composites, based on biopolymers with calcium phosphates, and cells can be applied. In the present work, a composite based on polyvinylpyrrolidone (PVP) and alginate (Alg) with carbonate hydroxyapatite (CHA) was prepared and characterized. The composite was investigated by X-ray diffraction, infrared spectroscopy, electron paramagnetic resonance (EPR) and scanning electron microscopy methods, and the microstructure, porosity, and swelling properties of the material were described. In vitro studies included the MTT test using mouse fibroblasts, and adhesion and survivability tests with human dental pulp stem cells (DPSC). The mineral component of the composite corresponded to CHA with an admixture of amorphous calcium phosphate. The presence of a bond between the polymer matrix and CHA particles was shown by EPR. The structure of the material was represented by micro- (30–190 μm) and nano-pores (average 8.71 ± 4.15 nm). The swelling measurements attested that CHA addition increased the polymer matrix hydrophilicity by 200%. In vitro studies demonstrated the biocompatibility of PVP-Alg-CHA (95 ± 5% cell viability), and DPSC located inside the pores. It was concluded that the PVP-Alg-CHA porous composite is promising for dentistry applications.

В лекции подробно рассматриваются современные представления об эпидемиологии, патогенезе, клинических проявлениях болезни/синдрома Бехчета, а также принципы диагностики, оценки активности и тяжести заболевания, подходы к терапии. Ключевые слова: болезнь/синдром Бехчета; клинические проявления; диагностика; терапия.

Six models of experimental immunogenic uveitis induced by injection of normal horse serum were tried in rabbits. A convenient working variant of the model was developed characterized by high activity and long duration of the inflammatory process in the eye. Creation of this model requires pre-sensitization (subcutaneous injection of 5 ml normal horse serum) followed by intravitreal injection of the resolving dose of horse serum on day 9. An adapted improved model of experimental immunogenic uveitis in rabbits is proposed.

Objective: to estimate changes of uveitis activity using BOS24 (Behсet's disease Ocular attack Score 24) during antiinflammatory and immunosuppressive therapy in patients with Behcet's disease (BD).Subjects and methods. 103 (75.6%) of the 138 patients with BD fulfilled the 1990 International Study Group for Behсet's Disease (ISGBD) criteria had eye lesions; 55 (53.4%) of the 103 patients had an exacerbation of uveitis. 55 patients with an exacerbation of uveitis were found to have active inflammation in 94 eyes. The activity of uveitis was monitored during anti-inflammatory and immunosuppressive therapy, by using BOS24 that consists of 6 parameters with maximal possible value 24.Results and discussion. The mean BOS24 for 94 eyes with active uveitis at baseline was 9.33±0.91. The most pronounced inflammatory changes were found in the posterior chamber of the eye, mainly in the area of the peripheral retina, rarely in the area of the fovea and in the optic disc. All the patients with an exacerbation of uveitis received systemic therapy with glucocorticoids, cyclosporine and/or azathioprine. After 8.92±3.47 months of treatment, the mean BOS2 decreased significantly (p < 0.001) to 2.20±1.02. The most substantial positive changes were noted in the anterior chamber of the eye (p = 0.03), vitreous humor (p < 0.01), and peripheral retina (p < 0.001).Conclusion. BOS24 is a reliable tool to quantify uveitis activity in patients with BD and its dynamics during antiinflammatory and immunosuppressive therapy.